Weight and breast cancer drugs: a study that never finished
NCT ID NCT02095184
First seen Apr 17, 2026 · Last updated May 10, 2026 · Updated 4 times
Summary
This study aimed to see if postmenopausal women with higher body fat respond differently to standard doses of aromatase inhibitors (anastrozole or letrozole) compared to women with lower body fat. About 42 women with hormone-sensitive breast cancer were planned to participate, but the study was terminated early. The goal was to measure changes in a tumor growth marker (Ki67) after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.